长春高新：子公司GenSci142胶囊国内生产药品注册临床试验申请获得受理

Core Viewpoint - Changchun Gaoxin's subsidiary, Jinsai Pharmaceutical, has received the acceptance notice for the clinical trial application of GenSci142 capsules from the National Medical Products Administration, indicating a significant step in expanding the company's product offerings and enhancing its competitive edge in the pharmaceutical industry [1] Group 1: Company Developments - Jinsai Pharmaceutical's GenSci142 capsules target Gardnerella bacteria and are characterized by rapid action, precise bactericidal effects, high efficiency in biofilm clearance, low risk of resistance, and local safety [1] - The acceptance of the clinical trial application is expected to help the company broaden its business structure and optimize its product lineup [1] Group 2: Industry Context - The pharmaceutical products involved are noted for their high technology, high risk, and high added value, indicating the complexities and challenges associated with drug development [1] - There remains uncertainty regarding the progress of the clinical trial, reflecting the inherent risks in the pharmaceutical industry [1]